<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383002</url>
  </required_header>
  <id_info>
    <org_study_id>20-5449</org_study_id>
    <nct_id>NCT04383002</nct_id>
  </id_info>
  <brief_title>High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)</brief_title>
  <official_title>Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novel therapies are desperately needed for treatment of COVID-19 patients. At present, there
      are no proven interventions to prevent progression of the disease or to rapidly treat
      patients with COVID-19 related respiratory failure. Data on the original coronavirus -SARS
      pneumonia suggested that high dose (&gt;160ppm) inhaled Nitric Oxide could have beneficial
      effects also on COVID-19, due to the genomic similarities between these two coronaviruses
      (1-3). This study will test whether high dose inhaled nitric oxide is safe and can reverse
      virus burden and respiratory failure in patients on mechanical ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 PCR status at completion of treatment (day 7) from tracheal aspirate</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard of care therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>iNO will be given at 160ppm for 6 hours, once a day, for 2 days</description>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laboratory confirmed COVID-19 infection defined with a positive RT-PCR

          -  Use of mechanical ventilation with or without ECMO

        Exclusion Criteria:

          -  Patients in other interventional clinical trials

          -  Patients with previous history of bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Cypel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Lister</last_name>
    <phone>416-340-4857</phone>
    <email>Jennifer.Lister@uhn.ca</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

